Published in Oncotarget on October 13, 2015
The Role of miR-378a in Metabolism, Angiogenesis, and Muscle Biology. Int J Endocrinol (2015) 0.82
Identification of clinically achievable combination therapies in childhood rhabdomyosarcoma. Cancer Chemother Pharmacol (2016) 0.75
Tumor-Activated Mesenchymal Stromal Cells Promote Osteosarcoma Stemness and Migratory Potential via IL-6 Secretion. PLoS One (2016) 0.75
Met, metastasis, motility and more. Nat Rev Mol Cell Biol (2003) 14.30
Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol (2010) 7.73
Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell (2003) 6.59
Targeting MET in cancer: rationale and progress. Nat Rev Cancer (2012) 6.43
Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud. Nature (1995) 6.13
The melanocyte differentiation program predisposes to metastasis after neoplastic transformation. Nat Genet (2005) 4.70
MiRNA-directed regulation of VEGF and other angiogenic factors under hypoxia. PLoS One (2006) 4.29
CXCR4-SDF-1 signalling, locomotion, chemotaxis and adhesion. J Mol Histol (2004) 4.08
MicroRNA-378 promotes cell survival, tumor growth, and angiogenesis by targeting SuFu and Fus-1 expression. Proc Natl Acad Sci U S A (2007) 3.92
Targeting the c-Met signaling pathway in cancer. Clin Cancer Res (2006) 3.57
Scatter factor/hepatocyte growth factor and its receptor, the c-met tyrosine kinase, can mediate a signal exchange between mesenchyme and epithelia during mouse development. J Cell Biol (1993) 3.32
Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival. Cancer Res (2007) 3.20
HGF/SF is present in normal adult skeletal muscle and is capable of activating satellite cells. Dev Biol (1998) 2.65
Synergism between INK4a/ARF inactivation and aberrant HGF/SF signaling in rhabdomyosarcomagenesis. Nat Med (2002) 2.58
Pax3:Fkhr interferes with embryonic Pax3 and Pax7 function: implications for alveolar rhabdomyosarcoma cell of origin. Genes Dev (2004) 2.54
Building muscle: molecular regulation of myogenesis. Cold Spring Harb Perspect Biol (2012) 2.52
Tumor-associated neutrophils: new targets for cancer therapy. Cancer Res (2011) 2.40
The muscle-specific microRNA miR-206 blocks human rhabdomyosarcoma growth in xenotransplanted mice by promoting myogenic differentiation. J Clin Invest (2009) 2.36
c-Met is a marker of pancreatic cancer stem cells and therapeutic target. Gastroenterology (2011) 2.27
MicroRNA-1/206 targets c-Met and inhibits rhabdomyosarcoma development. J Biol Chem (2009) 2.24
Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor. Proc Natl Acad Sci U S A (1997) 2.12
Hepatocyte growth factor effects on mesenchymal stem cells: proliferation, migration, and differentiation. Stem Cells (2005) 1.96
Cancer therapy: can the challenge be MET? Trends Mol Med (2005) 1.81
c-MET expression level in primary colon cancer: a predictor of tumor invasion and lymph node metastases. Clin Cancer Res (2003) 1.73
From Tpr-Met to Met, tumorigenesis and tubes. Oncogene (2007) 1.69
Dimerization mediated through a leucine zipper activates the oncogenic potential of the met receptor tyrosine kinase. Mol Cell Biol (1993) 1.64
Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma. Cancer Res (2006) 1.50
Alveolar rhabdomyosarcoma: is the cell of origin a mesenchymal stem cell? Cancer Lett (2008) 1.47
Mouse mesenchymal stem cells expressing PAX-FKHR form alveolar rhabdomyosarcomas by cooperating with secondary mutations. Cancer Res (2008) 1.36
MicroRNA-378 targets the myogenic repressor MyoR during myoblast differentiation. J Biol Chem (2011) 1.36
The biological role of HGF-MET axis in tumor growth and development of metastasis. Front Biosci (2008) 1.32
A natural hepatocyte growth factor/scatter factor autocrine loop in myoblast cells and the effect of the constitutive Met kinase activation on myogenic differentiation. J Cell Biol (1997) 1.30
Transgenic expression of tpr-met oncogene leads to development of mammary hyperplasia and tumors. J Clin Invest (1996) 1.27
The MET oncogene is a functional marker of a glioblastoma stem cell subtype. Cancer Res (2012) 1.21
miRNA expression profile in human osteosarcoma: role of miR-1 and miR-133b in proliferation and cell cycle control. Int J Oncol (2012) 1.18
Myc/miR-378/TOB2/cyclin D1 functional module regulates oncogenic transformation. Oncogene (2011) 1.16
MET is required for the recruitment of anti-tumoural neutrophils. Nature (2015) 1.16
Snail1 controls TGF-β responsiveness and differentiation of mesenchymal stem cells. Oncogene (2012) 1.15
Interplay between heme oxygenase-1 and miR-378 affects non-small cell lung carcinoma growth, vascularization, and metastasis. Antioxid Redox Signal (2013) 1.15
Activated ras and ret oncogenes induce over-expression of c-met (hepatocyte growth factor receptor) in human thyroid epithelial cells. Oncogene (1997) 1.12
Gelatinase B/MMP-9 in Tumour Pathogenesis and Progression. Cancers (Basel) (2014) 1.10
Modeling sarcomagenesis using multipotent mesenchymal stem cells. Cell Res (2011) 1.09
Differential expression of receptor tyrosine kinases (RTKs) and IGF-I pathway activation in human uterine leiomyomas. Mol Med (2008) 1.07
Snail1 controls bone mass by regulating Runx2 and VDR expression during osteoblast differentiation. EMBO J (2009) 1.00
Transcription factor Snail is a novel regulator of adipocyte differentiation via inhibiting the expression of peroxisome proliferator-activated receptor γ. Cell Mol Life Sci (2013) 0.99
Functional mapping of receptor tyrosine kinases in myxoid liposarcoma. Clin Cancer Res (2010) 0.95
Clinical significance of CXC chemokine receptor-4 and c-Met in childhood rhabdomyosarcoma. Clin Cancer Res (2008) 0.92
Conditional activation of MET in differentiated skeletal muscle induces atrophy. J Biol Chem (2006) 0.91
Deep Sequencing the microRNA profile in rhabdomyosarcoma reveals down-regulation of miR-378 family members. BMC Cancer (2014) 0.89
shRNA-mediated decreases in c-Met levels affect the differentiation potential of human mesenchymal stem cells and reduce their capacity for tissue repair. Tissue Eng Part A (2010) 0.87
The decreased metastatic potential of rhabdomyosarcoma cells obtained through MET receptor downregulation and the induction of differentiation. Cell Death Dis (2013) 0.86
Genetically modified adipose tissue-derived mesenchymal stem cells overexpressing CXCR4 display increased motility, invasiveness, and homing to bone marrow of NOD/SCID mice. Exp Hematol (2011) 0.86
C-Met pathway promotes self-renewal and tumorigenecity of head and neck squamous cell carcinoma stem-like cell. Oral Oncol (2014) 0.85
Inhibition of rhabdomyosarcoma's metastatic behavior through downregulation of MET receptor signaling. Folia Histochem Cytobiol (2009) 0.84
Hypoxia control to normalize pathologic angiogenesis: potential role for endothelial precursor cells and miRNAs regulation. Vascul Pharmacol (2012) 0.81
MicroRNAs and epigenetic mechanisms of rhabdomyosarcoma development. Int J Biochem Cell Biol (2014) 0.81
Efficient myoblast expansion for regenerative medicine use. Int J Mol Med (2014) 0.78
Rhabdomyosarcoma spheroids with central proliferation and differentiation. Cancer Res (1992) 0.77
MET receptor is a potential therapeutic target in high grade cervical cancer. Oncotarget (2015) 0.76
Differential expression of Snail1 transcription factor and Snail1-related genes in alveolar and embryonal rhabdomyosarcoma subtypes. Folia Histochem Cytobiol (2010) 0.76
The strategy of fusion genes construction determines efficient expression of introduced transcription factors. Acta Biochim Pol (2014) 0.76